Sung Yong Oh
About
Sung Yong Oh is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Sung Yong Oh has authored 236 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 151 papers in Oncology, 84 papers in Pathology and Forensic Medicine and 84 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sung Yong Oh's work include Lymphoma Diagnosis and Treatment (79 papers), Viral-associated cancers and disorders (42 papers) and Gastric Cancer Management and Outcomes (39 papers). Sung Yong Oh is often cited by papers focused on Lymphoma Diagnosis and Treatment (79 papers), Viral-associated cancers and disorders (42 papers) and Gastric Cancer Management and Outcomes (39 papers). Sung Yong Oh collaborates with scholars based in South Korea, United States and Taiwan. Sung Yong Oh's co-authors include Hyuk-Chan Kwon, Suee Lee, Hyojin Kim, Soon Il Lee, In Gyu Hwang, Cheolwon Suh, Sung Hyun Kim, Min Chan Kim, Jung Hun Kang and Hyuk‐Chan Kwon and has published in prestigious journals such as Advanced Materials, Journal of Clinical Oncology and Blood.
In The Last Decade
Sung Yong Oh
226 papers receiving 5.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sung Yong Oh South Korea | 35 | 3.3k | 1.8k | 1.7k | 1.5k | 824 | 236 | 5.6k | ||
| Hidetaka Yamamoto Japan | 42 | 2.1k 0.6× | 1.3k 0.7× | 2.7k 1.5× | 1.7k 1.1× | 1.6k 1.9× | 336 | 6.9k | ||
| Chang Sik Yu South Korea | 48 | 4.9k 1.5× | 952 0.5× | 1.6k 0.9× | 4.5k 3.1× | 623 0.8× | 375 | 8.5k | ||
| Ryoji Kushima Japan | 45 | 2.0k 0.6× | 1.1k 0.6× | 3.0k 1.7× | 2.7k 1.9× | 1.5k 1.8× | 321 | 7.1k | ||
| Virginie Verkarre France | 41 | 1.5k 0.5× | 841 0.5× | 1.6k 0.9× | 2.0k 1.4× | 1.4k 1.7× | 141 | 8.5k | ||
| George D. Demetri United States | 32 | 1.8k 0.5× | 433 0.2× | 2.0k 1.1× | 547 0.4× | 1.3k 1.6× | 104 | 5.0k | ||
| John F. Gibbs United States | 39 | 2.1k 0.6× | 639 0.4× | 1.6k 0.9× | 1.9k 1.3× | 705 0.9× | 150 | 4.7k | ||
| Sumiya Ishigami Japan | 43 | 3.0k 0.9× | 385 0.2× | 2.3k 1.3× | 2.0k 1.4× | 1.6k 1.9× | 240 | 6.4k | ||
| Hirotoshi Hasegawa Japan | 38 | 2.9k 0.9× | 603 0.3× | 1.3k 0.7× | 2.1k 1.4× | 538 0.7× | 175 | 4.6k | ||
| Florence Duffaud France | 42 | 1.8k 0.5× | 739 0.4× | 3.4k 2.0× | 1.0k 0.7× | 869 1.1× | 231 | 5.6k | ||
| Roderich E. Schwarz United States | 42 | 2.2k 0.7× | 350 0.2× | 2.4k 1.4× | 2.0k 1.4× | 1.2k 1.4× | 184 | 5.7k |
Countries citing papers authored by Sung Yong Oh
Since
Specialization
Citations
This map shows the geographic impact of Sung Yong Oh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sung Yong Oh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sung Yong Oh more than expected).
Fields of papers citing papers by Sung Yong Oh
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Sung Yong Oh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sung Yong Oh. The network helps show where Sung Yong Oh may publish in the future.
Co-authorship network of co-authors of Sung Yong Oh
This figure shows the co-authorship network connecting the top 25 collaborators of Sung Yong Oh. A scholar is included among the top collaborators of Sung Yong Oh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sung Yong Oh. Sung Yong Oh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Choi, Yoon Seok, Joonho Shim, Ka‐Won Kang, et al.. (2024). Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC Study. Cancer Research and Treatment. 57(1). 267–279.
2.
Koo, Dong‐Hoe, Jin Young Kim, Jae‐Joon Kim, et al.. (2024). Abstract CT216: Anti-EGFR in combination with paclitaxel as second-line therapy for gastric cancer with EGFR overexpression. Cancer Research. 84(7_Supplement). CT216–CT216.
3.
Li, Daneng, Hee Kyung Kim, Sun Young Kim, et al.. (2024). Results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody) in combo with pembrolizumab (Pembro) in patients (Pts) with metastatic microsatellite-stable (MSS) colorectal cancer (CRC).. Journal of Clinical Oncology. 42(3_suppl). 127–127.
4.
Kim, Yu Jung, Yu Jung Kim, Koung Jin Suh, et al.. (2024). Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second‐line treatment (EAGLES, Korean Cancer Study Group UN18‐06). Cancer. 131(1). e35609–e35609.
5.
Yoon, Dok Hyun, Hyungwoo Cho, Jae‐Cheol Jo, et al.. (2023). A phase 1 study of AT101, a novel anti-CD19 CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma.. Journal of Clinical Oncology. 41(16_suppl). 7522–7522.
6.
Won, Young‐Woong, Jin‐Hyoung Kang, Jung Hye Kwon, et al.. (2023). A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy. Cancer Research and Treatment. 55(4). 1096–1103.
7.
Kim, Hye Ryeon, Jung Hun Kang, Sung Hyun Kim, et al.. (2022). Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors. Cancers. 14(14). 3440–3440.
8.
Go, Se‐Il, Sang‐Cheol Lee, Woo Kyun Bae, et al.. (2021). Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3). European Journal of Cancer. 157. 21–30.
9.
Oh, Sung Yong & Jung Hun Kang. (2020). Dexamethasone-Induced Hiccups: An Important But Inconspicuous Symptom in Cancer. Journal of Palliative Medicine. 23(11). 1421–1421.
10.
Kim, Seok Jin, Dok Hyun Yoon, Hye Jin Kang, et al.. (2019). Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. BMC Cancer. 19(1).
11.
Kim, S.T., Ju-Bin Kang, Hyun Woo Lee, et al.. (2019). Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Annals of Oncology. 30(5). 788–795.
12.
Oh, Sung Yong, Suee Lee, Jeeyun Lee, et al.. (2018). Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer. Cancer Chemotherapy and Pharmacology. 83(3). 501–508.
13.
Lee, Ji Hyun, Sung Yong Oh, Ho Sup Lee, et al.. (2017). Pretreatment Nutritional Status and Cardiovascular Risk Factors Affect Survival of Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy. Blood. 130. 2856–2856.
14.
Hwang, In Gyu, Jung Hun Kang, Sung Yong Oh, et al.. (2015). Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. Supportive Care in Cancer. 24(1). 301–309.
15.
Oh, Sung Yong, Won Seog Kim, Jin Seok Kim, et al.. (2015). A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. Leukemia & lymphoma. 57(6). 1406–1412.
16.
Lee, Ho Jin, Dong Hyun Kim, So Yeon Kim, et al.. (2015). Analysis of factors affecting hemorrhagic diathesis and overall survival in patients with acute promyelocytic leukemia. The Korean Journal of Internal Medicine. 30(6). 884–890.
17.
Kwon, Hyuk-Chan, Sung Hyun Kim, Sung Yong Oh, et al.. (2012). Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers. 17(3). 216–222.
18.
Kwak, Jae‐Yong, Ho‐Young Yhim, Hye Jin Kang, et al.. (2009). Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphoma with Breast Involvement; Multi-Institutional Analysis of 98 Patients in Korea.. Blood. 114(22). 5024–5024.
19.
Oh, Sung Yong, Hyun Jin Kim, Tae Hyo Kim, et al.. (2009). Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer. Investigational New Drugs. 28(3). 343–349.
20.
Kwon, Hyuk-Chan, Sung Yong Oh, Suee Lee, Sunghyun Kim, & Hyojin Kim. (2007). Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: A pilot study. World Journal of Gastroenterology. 13(46). 6231–6231.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Hidetaka Yamamoto Breakdown of academic impact, for papers by Chang Sik Yu Breakdown of academic impact, for papers by Ryoji Kushima Breakdown of academic impact, for papers by Virginie Verkarre Breakdown of academic impact, for papers by George D. Demetri Breakdown of academic impact, for papers by John F. Gibbs Breakdown of academic impact, for papers by Sumiya Ishigami Breakdown of academic impact, for papers by Hirotoshi Hasegawa Breakdown of academic impact, for papers by Florence Duffaud Breakdown of academic impact, for papers by Roderich E. Schwarz